Towards Healthcare Research & Consulting

Contract Pharmaceutical Manufacturing Market Companies, Market Entry and Expansion Strategies

Date : 31 March 2026

Who are the Contract Pharmaceutical Manufacturing Market Top Vendors and What are Their Offerings?

Contract Pharmaceutical Manufacturing Market Companies are Lonza Group, Thermo Fisher Scientific (Patheon), Catalent, Inc., Samsung Biologics, WuXi AppTec

One place for the Market insights, stats, strategies and 30+ more features for your business. Access the dashboard today

Companies Headquarters Products Under Contract Pharmaceutical Manufacturing Services 
Lonza Group Basel, Switzerland Biologics, small molecule API, antibody-drug conjugates, and cell and gene therapies
Thermo Fisher Scientific (Patheon) Waltham, U.S. Sterile injectable, biologics, and oral solid dosage forms
Catalent, Inc. Somerset, U.S. Advanced drug delivery, gene therapy, oral solids, and biologics
Samsung Biologics Incheon, South Korea Monoclonal antibodies, ADCs, mRNA vaccines 
WuXi AppTec Shanghai, China Small molecules, peptides, cell and gene therapies, and oligonucleotides 
Recipharm AB Stockholm, Sweden Sterile injectables, advanced therapeutic medicinal products, and oral solids
Boehringer Ingelheim (BioXcellence)  Ingelheim, Germany Monoclonal antibodies, recombinant proteins, plasmid DNA, and fusion proteins.
Piramal Pharma Solutions Mumbai, India ADCs, potent APIs, sterile injectables, and complex oral solids
Akums Drugs & Pharmaceuticals Haridwar, India Tablets, capsules, injectables, and syrups
Siegfried Holding AG Zofingen, Switzerland Tablet, capsules, sterile vials, and ointments

Contract Pharmaceutical Manufacturing Market Value Chain Analysis

R&D

  • The R&D of the contract pharmaceutical manufacturing focuses on the development of advanced drug delivery systems, cell and gene therapy platforms, and AI-driven process optimization.
  • Key players: Lonza Group, Catalent, Inc., WuXi AppTec.

Clinical Trials and Regulatory Approvals

  • The manufacturing consistency, safety, and efficacy are evaluated in the clinical trials and regulatory approvals of the contract pharmaceutical manufacturing.
  • Key players: Samsung Biologics, Thermo Fisher Scientific (Patheon), Lonza Group.

Formulation and Final Dosage Preparation

  • The formulation and final dosage preparation of the contract pharmaceutical manufacturing focuses on optimization of drug stability, delivery formats, and solubility.
  • Key players: Recipharm AB, Catalent, Inc., Thermo Fisher Scientific (Patheon).

Packaging and Serialization

  • The packaging and serialization of the contract pharmaceutical manufacturing involves the use of secure primary and secondary containers, tamper-evident labelling, and unique track-and-trace coding.
  • Key players: Catalent, Inc., Thermo Fisher Scientific (Patheon), Akums Drugs & Pharmaceuticals.

Distribution to Hospitals, Pharmacies

  • The cold-chain logistics, last-mile delivery, and secure wholesale supply chains are responsible for the distribution of contract-manufactured pharmaceuticals to the hospitals and pharmacies.
  • Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Patient Support and Services

  • The reimbursement assistance, specialized home-delivery, and adherence programs are provided in the patient support and services by the contract pharmaceutical manufacturing facilities.
  • Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Market Growth 2026-2035

The global contract pharmaceutical manufacturing market size was estimated at USD 232.32 billion in 2025 and is predicted to increase from USD 255.41 billion in 2026 to approximately USD 599.3 billion by 2035, expanding at a CAGR of 9.94% from 2026 to 2035.

Contract Pharmaceutical Manufacturing Market Size is USD 255.41 Billion in 2026.

Recent Developments in the Contract Pharmaceutical Manufacturing Market

  • In March 2026, a strategic collaboration between Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio) and Wuhan Hiteck Biopharmaceutical Co., Ltd. was announced, where they will integrate preclinical development and commercial manufacturing capabilities of Hiteck with LexBio's 1.2 billion-compound AI-powered discovery platform to enhance the small-molecule therapies for the treatment of inflammatory diseases.
  • In March 2026, to support the pharmaceutical, diagnostics, and biotechnology organizations across the U.S., Canada, and Europe, and other markets by providing contract research organization ("CRO") services for custom aptamer discovery, machine-learning ("ML") classification, and biosensor enablement, was announced by the wholly-owned subsidiary, Triera Biosciences Ltd. of Zentek.